Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis

Non-Alcoholic Fatty Liver Disease Clinical Trial

— EVIDENCES IV  

Official title:

A Phase 2, Prospective, Multicenter, Double-blind, Randomized Study of Saroglitazar Magnesium 1 mg, 2 mg or 4 mg Versus Placebo in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03061721
• Other study ID #: SARO.16.005
• Status: Completed
• Phase: Phase 2
• Start date: April 6, 2017
• Est. completion date: December 15, 2020

Study information

• Verified date: December 2023
• Source: Zydus Therapeutics Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled study in up to 104 patients with a diagnosis of NAFLD and/or NASH. The study will be conducted over a period of up to 22 weeks and will include an optional Prescreening, Screening (Days -35 to -7) Phase, a 16-week Treatment Phase following randomization on Day 1. Patients will be randomly assigned in a ratio of 1:1:1:1 to receive Saroglitazar Magnesium 1mg or 2 mg or 4 mg or matching placebo once daily in the morning before breakfast for 16 Weeks. The primary endpoint of the study is percentage change from baseline in serum ALT levels at Week 16 in the Saroglitazar Magnesium groups as compared to the placebo group.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 106
• Est. completion date: December 15, 2020
• Est. primary completion date: October 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Males or females, 18 to 75 years of age, with body mass index (BMI) = 25 kg/m2.

2. Documented diagnosis of NAFLD established either by imaging (ultrasound, CT scan or MRI) or liver biopsy showing NASH or simple steatosis, within the 24 months preceding Visit 1. The diagnosis of NAFLD is made according to the American Association for the Study of Liver Diseases (AASLD) criteria (Chalasani et al. Hepatology 2012; 55:2005-2023).

3. ALT level of =50 U/L at Visit 1 and Visit 2 with =30% variance between the levels at Visit 1 and Visit 2.

4. Patient's demonstration of understanding of study requirements and treatment procedures, willingness to comply with all protocol-required evaluations; provision of written informed consent before any study specific tests or procedures are performed.

Exclusion Criteria:

1. Consumption of > 3 units of alcohol per day (> 21 units per week) if male and > 2 units of alcohol per day (>14 units per week) if female for at least 3 consecutive months in the 5 years preceding Visit 1 (Note: 1 unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits/hard liquor).

2. Presence of alternative causes of fatty liver, including:

1. Weight change >5% within the 3 months preceding Visit 1

2. Total parenteral nutrition, starvation or protein-calorie malnutrition within the 90 days preceding Visit 1.

3. Use of drugs associated with NAFLD for more than 12 consecutive weeks in the 1 year before Visit 1, including amiodarone, tamoxifen, methotrexate, systemic glucocorticoids, anabolic steroids, tetracycline, estrogens in doses higher than used in oral contraceptives, vitamin A, L asparaginase, valproate, chloroquine or antiretroviral drugs

3. Initiation of vitamin E at doses > 100 IU/day, or multivitamins containing > 100 IU/day of vitamin E in the 3 months preceding Visit 1.

4. Use of drugs with potential effect on NASH such as ursodeoxycholic acid, S-adenosylmethionine (SAM-e), betaine, pentoxifylline, obeticholic acid or milk thistle in the 3 months prior to Visit 1.

5. Changing doses of statins (simvastatin, pitavastatin, pravastatin, atorvastatin, fluvastatin, lovastatin, rosuvastatin) or fibrates (clofibrate, fenofibrate) in the 3 months preceding Visit 1.

6. Use of thiazolidinediones (pioglitazone, rosiglitazone).

7. Use of drugs that are known CYP2C8 inhibitors/substrate

8. History of bowel surgery (gastrointestinal (bariatric) surgery or undergoing evaluation for bariatric surgery for obesity, extensive small-bowel resection or orthotopic liver transplant (OLT) or listed for OLT.

9. History of other chronic liver disease (chronic hepatitis C, (HCV) infection, irrespective of their mRNA HCV assay status or active hepatitis B infection, (i.e., serum positive for hepatitis B surface antigen) or autoimmune hepatitis, cholestatic and metabolic liver diseases) or hemochromatosis

10. Patient has known cirrhosis, either based on clinical criteria or liver histology.

11. Patient with INR >1.3.

12. Type 1 diabetes mellitus.

13. Poorly controlled type 2 diabetes mellitus, i.e., glycosylated hemoglobin (HbA1c) > 9%.

14. Unstable cardiovascular disease, including:

1. unstable angina, (i.e., new or worsening symptoms of coronary heart disease within the 3 months preceding Visit 1), acute coronary syndrome within the 6 months preceding Visit 1, acute myocardial infarction within the 3 months preceding Visit 1 or heart failure of New York Heart Association class (III - IV) or worsening congestive heart failure, or coronary artery intervention, within the 6 months preceding Visit 1

2. history of (within 3 months preceding Visit 1) or current unstable cardiac dysrhythmias

3. uncontrolled hypertension (systolic blood pressure [BP] > 160 mmHg and/or diastolic BP > 100 mmHg)

4. stroke or transient ischemic attack within the 6 months preceding Visit 1.

15. History of myopathies or evidence of active muscle disease.

16. History of malignancy in the 5 years preceding Visit 1 and/or active neoplasm with the exception of resolved superficial nonmelanoma skin cancer.

17. Any of the following laboratory values:

1. Hemoglobin < 9 g/dL

2. White blood cell count < 2.5 × 103/µL

3. Neutrophil count < 1.5 × 103/µL

4. Platelets < 100 × 103/µL

5. Total Serum bilirubin > 1.5 mg/dL (except in patient with known Gilbert bilirubin where TB up to 2.5 mg/dL is allowed), if it is <1.5 mg/dL at screening and >30% variance in the levels at Visit 1 and Visit 2

6. Albumin < 3.2 g/dL

7. Serum creatinine >1.5 mg/dL

8. Serum ALT or AST > 250 IU/L at Visit 1 or Visit 2 .

18. Contraindications to Saroglitazar Magnesium or has any conditions affecting the ability to evaluate the effects of Saroglitazar Magnesium.

19. Known allergy, sensitivity or intolerance to the study drug, placebo or formulation ingredients.

20. Participation in any other therapeutic clinical study within the 3 months preceding Visit 1, including participation in any other NAFLD/NASH clinical trials.

21. History of bladder disease and/or hematuria or has current hematuria except due to a urinary tract infection.

22. Illicit substance abuse within the 12 months preceding Visit 1.

23. Pregnancy-related exclusions, including:

1. Pregnant/lactating female (including a positive serum pregnancy test at Visit 1)

2. A male patient has to use a condom with spermicide, and the female partner of the male patient has to use an intrauterine device OR a diaphragm with spermicide OR oral contraceptive pills.

3. If a male patient has undergone a vasectomy, the female partner does not have to use any contraception.

4. A female patient has to use either an intrauterine device OR a diaphragm with spermicide OR oral contraceptive pills. The male partner of the female patient has to use a condom with spermicide.

5. If the female patient is surgically sterilized for at least the 6 months preceding Visit 1 or postmenopausal, defined as at least 12 months with no menses and without an alternative cause, the male partner of the female patient does not have to use any contraception.

24. History or other evidence of severe illness or any other conditions that would make the patient, in the opinion of the investigator, unsuitable for the study (such as poorly controlled psychiatric disease, HIV, coronary artery disease or active gastrointestinal conditions that might interfere with drug absorption).

Related Conditions & MeSH terms

• Fatty Liver
• Liver Diseases
• Non-alcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Intervention

Drug:
• Saroglitazar magnesium 1 mg
Patients randomly assigned to this group will receive Saroglitazar magnesium 1 mg tablet orally once daily for 16 weeks.
• Saroglitazar magnesium 2 mg
Patients randomly assigned to this group will receive Saroglitazar magnesium 2 mg tablet orally once daily for 16 weeks.
• Saroglitazar magnesium 4 mg
Patients randomly assigned to this group will receive Saroglitazar magnesium 4 mg tablet orally once daily for 16 weeks.
• Placebos
Patients randomly assigned to this group will receive placebo tablet orally once daily for 16 weeks.

Locations

Country	Name	City	State
United States	University of Michigan	Ann Arbor	Michigan
United States	Mercy Medical Center	Baltimore	Maryland
United States	Precision Research	Chula Vista	California
United States	Liver Consultants	Dallas	Texas
United States	Henry Ford Hospital	Detroit	Michigan
United States	University of Florida	Gainesville	Florida
United States	Gastro One	Germantown	Tennessee
United States	AIG Research	Hermitage	Tennessee
United States	Indiana University	Indianapolis	Indiana
United States	Cedars-Sinai Medical Center	Los Angeles	California
United States	Awasty Research Network, LLC	Marion	Ohio
United States	Schiff Center for Liver Diseases/University of Miami	Miami	Florida
United States	Catalina Research Institute	Montclair	California
United States	Avail Clinical Research	Orange City	Florida
United States	California liver research institute	Pasadena	California
United States	Einstein Medical Center	Philadelphia	Pennsylvania
United States	The Liver Institute	San Antonio	Texas
United States	Medical Associates Research Group	San Diego	California
United States	Precision Research	San Diego	California
United States	Swedish Medical Center	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Zydus Therapeutics Inc.

Country where clinical trial is conducted

United States, 

References & Publications (2)

Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012 Jun;55(6):2005-23. doi: 10.1002/hep.25762. No abstract available. — View Citation

Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N. Saroglitazar, a PPAR-alpha/gamma Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology. 2021 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage change from baseline in serum ALT levels at Week 16	Percentage change from baseline in serum ALT levels at Week 16 in the Saroglitazar Magnesium groups as compared to the placebo group	16 Weeks
Secondary	Change in liver fat content as measured by magnetic resonance imaging-derived proton density-fat fraction (MRI-PDFF)	Change in liver fat content as measured by magnetic resonance imaging-derived proton in Saroglitazar Magnesium groups as compared to the placebo group	16 Weeks
Secondary	Proportion of patients with sustain decrease in serum ALT levels	Proportion of patients with sustain decrease in serum ALT levels in Saroglitazar Magnesium groups as compared to the placebo group	16 Weeks
Secondary	Changes in cytokeratin-18	Changes in cytokeratin-18 in Saroglitazar Magnesium groups as compared to the placebo group	16 Weeks
Secondary	Changes in enhanced liver fibrosis	Changes in enhanced liver fibrosis in Saroglitazar Magnesium groups as compared to the placebo group	16 Weeks
Secondary	Change in aspartate aminotransferase-to-platelet ratio index	Change in aspartate aminotransferase-to-platelet ratio index in Saroglitazar Magnesium groups as compared to the placebo group	16 Weeks
Secondary	Pharmacokinetics of Saroglitazar Magnesium: maximum plasma concentration (Cmax)	Maximum plasma concentration (Cmax) of Saroglitazar	16 Weeks
Secondary	Time to reach maximum plasma concentration (Tmax)	Time to reach maximum plasma concentration (Tmax) of saroglitazar	16 Week
Secondary	Terminal half life (t1/2)	Terminal half life (t1/2) of saroglitazar	16 Weeks
Secondary	Area under the curve from the time of dosing to the last measurable concentration (AUC0-t)	Area under the curve from the time of dosing to the last measurable concentration for saroglitazar	16 Week
Secondary	Area under the curve from the time of dosing to the infinity (AUC 0-inf)	Area under the curve from the time of dosing to the infinity (AUC 0-inf) for Saroglitazar	16 Week
Secondary	Elimination rate constant (?z)	Elimination rate constant (?z) for saroglitazar	16 Week
Secondary	Apparent volume of distribution (Vd/F)	Apparent volume of distribution (Vd/F) for Saroglitazar	16 Week
Secondary	Apparent clearance (CL/F)	Apparent clearance (CL/F) for Saroglitazar	16 Week
Secondary	Change in quality of life assessed by the Short-Form 36 Health Survey	Quality of life will be assessed by the Short-Form 36 Health Survey	16 Week
Secondary	Safety and tolerability of Saroglitazar Magnesium	Assessed by incidence of adverse events	16 Weeks

External Links

•   Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of
•   Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N. Saroglitazar, a PPAR-alpha/gamma Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.